Roche is expanding its collaboration with Aileron Therapeutics to discover, develop and commercialize stapled peptide drugs. The two companies will now begin work on a third program focused on inflammatory diseases. The collaboration has a potential value of $1.1 billion and encompasses as many as five programs of strategic importance to Roche. Also, Aileron has achieved a key milestone under the collaboration, triggering a milestone payment related to in vivo proof-of-concept against one of Ro...